Source 1primary paper2025MED
Toolkit/chimeric antigen receptor macrophage
chimeric antigen receptor macrophage
Also known as: CAR-M, CAR macrophage, CAR-Ms
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Engineering chimeric antigen receptors (CARs) to endow macrophages with anti-tumor capacities demonstrated encouraging efficacy, particularly in enhancing tumor-targeted phagocytosis. Furthermore, CAR macrophages (CAR-Ms) orchestrate adaptive immunity through secreting pro-inflammatory cytokines and presenting tumor antigens, thereby activating cytotoxic T lymphocyte responses.
Usefulness & Problems
Why this is useful
CAR-Ms are engineered macrophages bearing chimeric antigen receptors to promote anti-tumor functions. The abstract attributes tumor-targeted phagocytosis, pro-inflammatory cytokine secretion, and tumor-antigen presentation to this platform.; solid tumor cancer immunotherapy; enhancing tumor-targeted phagocytosis; activating adaptive anti-tumor immunity
Source:
CAR-Ms are engineered macrophages bearing chimeric antigen receptors to promote anti-tumor functions. The abstract attributes tumor-targeted phagocytosis, pro-inflammatory cytokine secretion, and tumor-antigen presentation to this platform.
Source:
solid tumor cancer immunotherapy
Source:
enhancing tumor-targeted phagocytosis
Source:
activating adaptive anti-tumor immunity
Problem solved
The source presents CAR-Ms as a way to therapeutically reprogram macrophages for cancer immunotherapy, especially in therapy-refractory solid tumors.; reprogramming macrophages toward anti-tumor activity in solid malignancies; addressing therapy-refractory solid tumors with a macrophage-based immunotherapy modality
Source:
The source presents CAR-Ms as a way to therapeutically reprogram macrophages for cancer immunotherapy, especially in therapy-refractory solid tumors.
Source:
reprogramming macrophages toward anti-tumor activity in solid malignancies
Source:
addressing therapy-refractory solid tumors with a macrophage-based immunotherapy modality
Problem links
addressing therapy-refractory solid tumors with a macrophage-based immunotherapy modality
LiteratureThe source presents CAR-Ms as a way to therapeutically reprogram macrophages for cancer immunotherapy, especially in therapy-refractory solid tumors.
Source:
The source presents CAR-Ms as a way to therapeutically reprogram macrophages for cancer immunotherapy, especially in therapy-refractory solid tumors.
reprogramming macrophages toward anti-tumor activity in solid malignancies
LiteratureThe source presents CAR-Ms as a way to therapeutically reprogram macrophages for cancer immunotherapy, especially in therapy-refractory solid tumors.
Source:
The source presents CAR-Ms as a way to therapeutically reprogram macrophages for cancer immunotherapy, especially in therapy-refractory solid tumors.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
activation of cytotoxic t lymphocyte responsesantigen presentationchimeric antigen receptor-mediated target recognitionphagocytosispro-inflammatory cytokine secretionTechniques
No technique tags yet.
Target processes
recombinationImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: regulator
The platform requires macrophages and CAR engineering. The abstract does not specify vector, manufacturing process, or exact receptor design components.; requires engineering macrophages with chimeric antigen receptors
The abstract does not establish that CAR-Ms solve all barriers to solid tumor treatment or define failure modes, safety limits, or durability constraints.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Engineering chimeric antigen receptors into macrophages has shown encouraging anti-tumor efficacy, particularly by enhancing tumor-targeted phagocytosis.
Engineering chimeric antigen receptors (CARs) to endow macrophages with anti-tumor capacities demonstrated encouraging efficacy, particularly in enhancing tumor-targeted phagocytosis.
CAR macrophages can orchestrate adaptive immunity by secreting pro-inflammatory cytokines and presenting tumor antigens, thereby activating cytotoxic T lymphocyte responses.
Furthermore, CAR macrophages (CAR-Ms) orchestrate adaptive immunity through secreting pro-inflammatory cytokines and presenting tumor antigens, thereby activating cytotoxic T lymphocyte responses.
CAR-Ms are presented as potent immunotherapeutic agents against therapy-refractory solid malignancies.
These multifaceted properties establish CAR-Ms as potent immunotherapeutic agents against therapy-refractory solid malignancies.
Approval Evidence
1 source3 linked approval claimsfirst-pass slug chimeric-antigen-receptor-macrophage
Engineering chimeric antigen receptors (CARs) to endow macrophages with anti-tumor capacities demonstrated encouraging efficacy, particularly in enhancing tumor-targeted phagocytosis. Furthermore, CAR macrophages (CAR-Ms) orchestrate adaptive immunity through secreting pro-inflammatory cytokines and presenting tumor antigens, thereby activating cytotoxic T lymphocyte responses.
Source:
functional capabilitysupports
Engineering chimeric antigen receptors into macrophages has shown encouraging anti-tumor efficacy, particularly by enhancing tumor-targeted phagocytosis.
Engineering chimeric antigen receptors (CARs) to endow macrophages with anti-tumor capacities demonstrated encouraging efficacy, particularly in enhancing tumor-targeted phagocytosis.
Source:
mechanism of actionsupports
CAR macrophages can orchestrate adaptive immunity by secreting pro-inflammatory cytokines and presenting tumor antigens, thereby activating cytotoxic T lymphocyte responses.
Furthermore, CAR macrophages (CAR-Ms) orchestrate adaptive immunity through secreting pro-inflammatory cytokines and presenting tumor antigens, thereby activating cytotoxic T lymphocyte responses.
Source:
therapeutic positioningsupports
CAR-Ms are presented as potent immunotherapeutic agents against therapy-refractory solid malignancies.
These multifaceted properties establish CAR-Ms as potent immunotherapeutic agents against therapy-refractory solid malignancies.
Source:
Comparisons
Source-stated alternatives
The abstract references future trends based on CAR-T therapy evolution, implying CAR-T as a nearby comparator framework, but does not provide a direct head-to-head comparison.
Source:
The abstract references future trends based on CAR-T therapy evolution, implying CAR-T as a nearby comparator framework, but does not provide a direct head-to-head comparison.
Source-backed strengths
multifaceted activity including phagocytosis, cytokine secretion, and antigen presentation; positioned as potent agents against therapy-refractory solid malignancies
Source:
multifaceted activity including phagocytosis, cytokine secretion, and antigen presentation
Source:
positioned as potent agents against therapy-refractory solid malignancies
Compared with CAR-T
The abstract references future trends based on CAR-T therapy evolution, implying CAR-T as a nearby comparator framework, but does not provide a direct head-to-head comparison.
Shared frame: source-stated alternative in extracted literature
Strengths here: multifaceted activity including phagocytosis, cytokine secretion, and antigen presentation; positioned as potent agents against therapy-refractory solid malignancies.
Source:
The abstract references future trends based on CAR-T therapy evolution, implying CAR-T as a nearby comparator framework, but does not provide a direct head-to-head comparison.
Compared with CAR-T cells
The abstract references future trends based on CAR-T therapy evolution, implying CAR-T as a nearby comparator framework, but does not provide a direct head-to-head comparison.
Shared frame: source-stated alternative in extracted literature
Strengths here: multifaceted activity including phagocytosis, cytokine secretion, and antigen presentation; positioned as potent agents against therapy-refractory solid malignancies.
Source:
The abstract references future trends based on CAR-T therapy evolution, implying CAR-T as a nearby comparator framework, but does not provide a direct head-to-head comparison.
Compared with CAR-T therapy
The abstract references future trends based on CAR-T therapy evolution, implying CAR-T as a nearby comparator framework, but does not provide a direct head-to-head comparison.
Shared frame: source-stated alternative in extracted literature
Strengths here: multifaceted activity including phagocytosis, cytokine secretion, and antigen presentation; positioned as potent agents against therapy-refractory solid malignancies.
Source:
The abstract references future trends based on CAR-T therapy evolution, implying CAR-T as a nearby comparator framework, but does not provide a direct head-to-head comparison.
Compared with Chimeric Antigen Receptor (CAR) T-cell therapy
The abstract references future trends based on CAR-T therapy evolution, implying CAR-T as a nearby comparator framework, but does not provide a direct head-to-head comparison.
Shared frame: source-stated alternative in extracted literature
Strengths here: multifaceted activity including phagocytosis, cytokine secretion, and antigen presentation; positioned as potent agents against therapy-refractory solid malignancies.
Source:
The abstract references future trends based on CAR-T therapy evolution, implying CAR-T as a nearby comparator framework, but does not provide a direct head-to-head comparison.
Compared with chimeric antigen receptor T cells
The abstract references future trends based on CAR-T therapy evolution, implying CAR-T as a nearby comparator framework, but does not provide a direct head-to-head comparison.
Shared frame: source-stated alternative in extracted literature
Strengths here: multifaceted activity including phagocytosis, cytokine secretion, and antigen presentation; positioned as potent agents against therapy-refractory solid malignancies.
Source:
The abstract references future trends based on CAR-T therapy evolution, implying CAR-T as a nearby comparator framework, but does not provide a direct head-to-head comparison.
Compared with Chimeric antigen receptor T-cell therapy
The abstract references future trends based on CAR-T therapy evolution, implying CAR-T as a nearby comparator framework, but does not provide a direct head-to-head comparison.
Shared frame: source-stated alternative in extracted literature
Strengths here: multifaceted activity including phagocytosis, cytokine secretion, and antigen presentation; positioned as potent agents against therapy-refractory solid malignancies.
Source:
The abstract references future trends based on CAR-T therapy evolution, implying CAR-T as a nearby comparator framework, but does not provide a direct head-to-head comparison.
Ranked Citations
- 1.